

Cynata Entitlement Offer Opens

Melbourne, Australia; 21 December 2020: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to open to eligible shareholders a 1 for 15 non-renounceable entitlement offer (**Entitlement Offer**), as announced on 11 December 2020.

The entitlement offer booklet, personalised entitlement forms and acceptance forms will be dispatched to eligible shareholders today. The Entitlement Offer is planned to remain open to 5:00pm (AEDT) on Wednesday, 13 January 2021. A copy of the offer booklet and personalised entitlement and acceptances forms is also available online via the registry website: <https://investor.automic.com.au>.

The Entitlement Offer plans to raise up to A\$5.5m and follows the successful placement which will raise A\$15m, led by healthcare investor BioScience Managers Translation Fund I (BMTFI). The proceeds raised will primarily fund an expanded clinical development pipeline into additional high priority targets including idiopathic pulmonary fibrosis (IPF), renal transplantation and diabetic foot ulcers (DFU). Funds will also be used to optimise and expand manufacturing capabilities and progress Cynata’s US regulatory strategy to better position the company to commercialise its MSC products.

Dr. Ross Macdonald, Cynata’s CEO and MD, said:

“We appreciate the ongoing support of existing shareholders and are pleased to make the same offer as the recent Placement with the entitlement offer that opens today. This comes at a key time of growth for Cynata with the recent commencement of our Phase 3 trial in osteoarthritis, the first Phase 3 ever conducted of an iPSC-derived MSC therapy, in addition to our planned pipeline expansion into three high needs conditions with significant market opportunities, backed by the very promising pre-clinical studies undertaken to date. We have included a top up facility which enables shareholders who take up their entitlement in full the opportunity to apply for additional shares in excess of their pro-rata entitlement. With the additional capital Cynata is in a strong position to accelerate further development of our unique Cymerus™ platform.”

Indicative Capital Raising timetable¹

Event	Date
Record date for Entitlement Offer	Wednesday, 16 December 2020
Despatch of Offer Booklet and Entitlement Offer opens	Monday, 21 December 2020
Entitlement Offer closes	Wednesday, 13 January 2021
Announcement of Entitlement Offer results	Monday, 18 January 2021
New Shares issued under the Entitlement Offer	Wednesday, 20 January 2021
Allotment and commencement of trading of New Shares under the Entitlement Offer	Thursday, 21 January 2021

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO



CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata has active clinical trials, using its Cymerus™ MSCs for a Phase 3 trial in osteoarthritis and a Phase 2 trial in severe complications arising from COVID-19. Cynata plans to advance into trials for GvHD (through licensee Fujifilm) and critical limb ischemia. Cynata is planning for additional clinical programs in further indications (including idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers), following encouraging pre-clinical data. In addition, Cynata has demonstrated utility of its Cymerus™ MSC technology in preclinical models of asthma, diabetic wounds, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

¹ This timetable is indicative only and subject to change. The Company reserves the right to amend the dates at its discretion and without notice, subject to the ASX Listing Rules and the *Corporations Act 2001 (Cth)*. All times are AEDT